烟酰胺核苷在帕金森病中的研究进展  

Research progress of nicotinamide nucleoside in Parkinson's disease

作　　者：文雪怡 李清华[1] WEN Xueyi;LI Qinghua(Guangxi Key Laboratory of Brain and Cognition,Guilin Medical University,Guilin 541004,China)

机构地区：[1]桂林医学院广西脑与认识重点实验室,广西桂林541004

出　　处：《华夏医学》2019年第4期157-161,共5页Acta Medicinae Sinica

摘　　要：帕金森病(Parkinson's disease,PD)是一种与线粒体功能障碍有关的神经退行性疾病,随着年龄增长,机体中烟酰胺腺喋吟二核苷酸(nicotinamide adenine dinucleotide,NAD+)水平不断下降,而NAD+的耗竭正是线粒体功能障碍的关键因素。当NAD+作为一种共底物被消耗时,就需要补充NAD+前体,烟酰胺核苷(nicotinamide riboside,NR)是NAD+的一种维生素前体,存在于膳食中。研究发现,口服NR可以改善帕金森动物模型的症状,目前具体机制众说纷纭。笔者就国内外对NR和帕金森病的研究,探讨烟酰胺核苷在帕金森病中的作用及研究进展。Parkinson's disease(PD)is an age-related neurodegenerative disorder associated with mitochondrial dysfunction.The level of Nicotinamide Adenine Dinucleotid(NAD+)decreases with aging,and the depletion of NAD+is a key factor in mitochondrial dysfunction.When NAD+is consumed as a cosubstrate,it is necessary to supply the NAD+precursor.Nicotinamide Riboside(NR)is a vitamin precursor of NAD+,being present in the diet.Studies have found that oral NR can improve the symptoms in Parkinson's animal model.The specific mechanism remains to be determined.In this paper,the authors investigate the role of NR in Parkinson's disease and its research progress based on the researches of NR and Parkinson's disease home and abroad.

关 键 词：烟酰胺核苷 线粒体功能障碍 帕金森病 

分 类 号：R742.5[医药卫生—神经病学与精神病学] R741.05[医药卫生—临床医学]